Clinical Trial Update: A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy [Phase 2]

View source ↗

Summary

This Phase 2 study investigates adaptive dosing of the combination of ipilimumab and nivolumab for metastatic melanoma and is currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Metastatic Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING